Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10895265 | Best Practice & Research Clinical Haematology | 2005 | 18 Pages |
Abstract
Heavy chain diseases (HCDs) are rare B-cell lymphoplasma-cell proliferative disorders characterized by production of truncated monoclonal immunoglobulin heavy chains without associated light chains. HCDs involving the three main immunoglobulin classes have been described; α-HCD is the most common and has the most uniform presentation, γ- and μ-HCDs have variable clinical presentations and histopathologic features. HCDs can be thought of as variant types of non-Hodgkin lymphoma: α-HCD presents as an extranodal marginal-zone lymphoma of mucosa-associated lymph-node tissue, γ-HCD as lymphoplasmacytoid non-Hodgkin lymphoma, and μ-HCD as small lymphocytic non-Hodgkin lymphoma or chronic lymphocytic leukemia. Diagnosis of HCD requires documentation of a deleted immunoglobulin heavy chain without a bound light chain in the serum or urine. Prognosis is variable, and no standardized effective treatment programs are available except for α-HCD, which in its early stage may respond to antibiotics.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Dietlind L. (Consultant, Division of General Internal Medicine, Mayo Clinic; Associate Professor of Medicine, Mayo Clinic College of Medicine), Robert A. (Consultant, Division of Hematology, Mayo Clinic; Professor of Medicine and of Laboratory Medicine,